Brief: SymBio Pharmaceuticals commences phase III clinical trial for TREAKISYM
31/08/2017 08:03
Aug 31(Reuters) - SymBio Pharmaceuticals Ltd 4582.T
* Says it initiated a phase 3 study of the anticancer drug
TREAKISYM for the indication of relapsed/refractory diffuse
large B-cell lymphoma
Source text in Japanese:https://goo.gl/ftLXxp
Further company coverage: 4582.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 10 62674724;
Reuters Messaging: huafang.zhang.reuters.com@reuters.net))